Randomized Trial Replication Using Observational Data for Comparative Effectiveness of Secukinumab and Ustekinumab in Psoriasis | Zendy

Z.Z.N. Yiu | Zendy; K.J. Mason | Zendy; Philip Hampton | Zendy; Nick J. Reynolds | Zendy; Catherine Smith | Zendy; Mark Lunt | Zendy; C.E.M. Griffiths | Zendy; Richard B. Warren | Zendy

Open Access

Randomized Trial Replication Using Observational Data for Comparative Effectiveness of Secukinumab and Ustekinumab in Psoriasis

Author(s) -

Z.Z.N. Yiu,

K.J. Mason,

Philip Hampton,

Nick J. Reynolds,

Catherine Smith,

Mark Lunt,

C.E.M. Griffiths,

Richard B. Warren

Publication year - 2020

Publication title -

jama dermatology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.128

H-Index - 166

eISSN - 2168-6084

pISSN - 2168-6068

DOI - 10.1001/jamadermatol.2020.4202

Subject(s) - ustekinumab , secukinumab , medicine , observational study , psoriasis , randomized controlled trial , dermatology , plaque psoriasis , oncology , adalimumab , disease , psoriatic arthritis

Treatments for psoriasis may be less effective in everyday practice than in clinical trials. Emulating a target trial using data from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR) can provide treatment effect estimates that are robust and can inform both clinicians and regulatory bodies.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research